Evidence map›Paper›PMID 38409483›Full record

ArticleJournal of natural medicines2024

Integrating network pharmacology and experimental models to identify notoginsenoside R1 ameliorates atherosclerosis by inhibiting macrophage NLRP3 inflammasome activation.

Jingyue Yu, Jinyu Hu, Margaret Baldini, Huan Lei, Lei Li, Shanshan Luo, Jielian Wu, Xupin Liu, Dan Shan, Yanfei Xie and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of natural medicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Jingyue YuSchool of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang, 330013, China.
Jinyu HuSchool of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang, 330013, China.
Margaret BaldiniCenter for Metabolic Disease Research and Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Huan LeiSchool of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang, 330013, China.
Lei LiSchool of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang, 330013, China.
Shanshan LuoSchool of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang, 330013, China.
Jielian WuSchool of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang, 330013, China.
Xupin LiuNMPA Key Laboratory of Quality Evaluation of Traditional Chinese Patent Medicine, Jiangxi Institute for Drug Control, Nanchang, 330029, China.
Dan ShanCenter for Metabolic Disease Research and Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Yanfei XieCenter for Translational Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang, 330006, China.
Haihong FangSchool of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang, 330013, China. fanghh@jxstnu.edu.cn.
Jun YuCenter for Metabolic Disease Research and Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Jiangxi Science and Technology Normal University · CNTemple University · USJiang Xi Institute for Drug Control · CNJiangxi University of Traditional Chinese Medicine · CN

Funding

Science and Technology Project of Jiangxi Provincial Department of Education GJJ2201302the Graduate Innovation Special Fund Project YC2021-X21
6 · The paper itself

Abstract

Atherosclerosis is a cardiovascular disease, accounting for the most common mortality cause worldwide. Notoginsenoside R1 (NGR1) is a characteristic saponin of Radix notoginseng that exhibits anti-inflammatory and antioxidant effects while modulating lipid metabolism. Evidence suggests that NGR1 exerts cardioprotective, neuroprotective, and anti-atherosclerosis effects. However, underlying NGR1 mechanisms alleviating atherosclerosis (AS) have not been examined. This study used a network pharmacology approach to construct the drug-target-disease correlation and protein-protein interaction (PPI) network of NGR1 and AS. Moreover, functional annotation and pathway enrichment analyses deciphered the critical biological processes and signaling pathways potentially regulated by NGR1. The protective effect of NGR1 against AS and the underlying mechanism(s) was assessed in an atherogenic apolipoprotein E-deficient (ApoE

Indexed as

AtherosclerosisGinsenosidesInflammasomesMacrophagesNetwork PharmacologyNLR Family, Pyrin Domain-Containing 3 ProteinAnimalsApolipoproteins EDisease Models, AnimalLipoproteins, LDLMaleMiceMice, Inbred C57BLMolecular Docking SimulationSignal TransductionApolipoproteins EGinsenosidesInflammasomesLipoproteins, LDLNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mousenotoginsenoside R1oxidized low density lipoproteinAtherosclerosisMacrophageNetwork pharmacologyNLRP3 inflammasomeNotoginsenoside R1

Identifiers

PMID38409483
OpenAlexW4392169908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.